GuerraS. Overlap of asthma and chronic obstructive pulmonary disease. Curr Opin Pulm Med, 2004; 11(1):7-13.
2.
SorianoJB, DavisKJ, ColemanB, VisickG, ManninoD, PrideNB. The proportional Venn diagram of obstructive lung disease. Two approximations from the United States and the United Kingdom. Chest, 2003; 124(2):474-481.
BurrowsB, MartinezFD, HalonenM, BarbeeRA, ClineMG. Association of asthma with serum IgE levels and skin-test reactivity to allergens. N Engl J Med, 1989; 320(5):272-277.
5.
HurstJR, VestboJ, AnzuetoA, LocantoreN, MullerovaH, Tal-SingerR, et al; Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) investigators. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med, 2010; 363(12):1128-1138.
6.
FletcherC, PetoR. The natural history of chronic airflow obstruction. BMJ, 1977; 1(6077):1645-1648.
7.
LangeP, ParnerJ, VestboJ, SchnohrP, JensenG. A 15-year follow-up study of ventilatory function in adults with asthma. N Engl J Med, 1998; 339(17):1194-1200.
8.
WenzelSE, SchwartzLB, LangmackEL, HallidayJL, TrudeauJB, GibbsRL, ChuHW. Evidence that severe asthma can be divided pathologically into two inflammatory subtypes with distinct physiologic and clinical characteristics. Am J Respir Crit Care Med, 1999; 160(3):1001-1008.
9.
BarnesPJ. Glucocorticoids: current and future directions. Br J Pharmacol, 2011; 163(1):29-43. DOI: 10.1111/j.1476-5381.2010.01199.x.
10.
SaettaM, Di StefanoA, MaestrelliP, TuratoG, RuggieriMP, RoggeriA, et al. Airway eosinophilia in chronic bronchitis during exacerbations. Am J Respir Crit Care Med, 1994; 150(6 Pt 1):1646-1652.
11.
KestenS, RebuckAS. Is the short-term response to inhaled beta-adrenergic agonist sensitive or specific for distinguishing asthma and COPD?. Chest, 1994; 105(4):1042-1045.
12.
TashkinDP, AltoseMD, BleeckerER, ConnettJE, KannerRE, LeeWW, WiseR; Lung Health Study Research Group. The Lung Health Study: airway responsiveness to inhaled methacholine in smokers with mild to moderate airflow limitation. Am Rev Respir Dis, 1992; 145(2 Pt 1):301-310.
13.
YanK, SalomeCM, WoolcockAJ. Prevalence and nature of bronchial hyperresponsiveness in subjects with chronic obstructive pulmonary disease. Am Rev Respir Dis, 1985; 132(1):25-29.
14.
TashkinDP: Measurement and significance of the bronchodilator response. In: JenneJW, editor. Bronchodilators: theory and practice. New York: Marcel Dekker; 1987:535-613.
15.
ManninoDM, GagnonRC, PettyTL, LydickE. Obstructive lung disease and low lung function in adults in the United States: data from the National Health and Nutrition Survey, 1988-1994. Arch Intern Med, 2000; 160(11):1683-1689.
16.
AnthonisenNR, ConnettJE, KileyJP, AltoseMD, BaileyWC, BuistAS, et al; Lung Health Study Research Group. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. JAMA, 1994; 272(19):1497-1505.
17.
TashkinDP, CelliB, DecramerM, LiuD, BurkhartD, CassinoC, KestenS. Bronchodilator responsiveness in patients with COPD. Eur Respir J, 2008; 31(4):742-750.
18.
CalverleyPM, BurgePS, SpencerS, AndersonJA, JonesPW; Inhaled Steroids in Obstructive Lung Disease in Europe (ISOLDE) Study Investigators. Bronchodilator reversibility testing in chronic obstructive pulmonary disease. Thorax, 2003; 58:659-664.
19.
DorinskyPM, ReisnerC, FergusonGT, MenjogeSS, SerbyCW, WitekTJ. The combination of ipratropium and albuterol optimizes pulmonary function reversibility testing in patients with COPD. Chest, 1999; 115(4):966-971.
20.
NewtonMF, O'DonnellDE, ForkertL. Response of lung volumes to inhaled salbutamol in a large population of patients with severe hyperinflation. Chest, 2002; 121(4):1042-1050.
21.
CelliB, TashkinDP, RennardSI, McElhattanJ, MartinU. Bronchodilator responsiveness and onset of effect with budesonide/formoterol pMDI in patients with COPD. Respir Med, 2011; 105(8):1176-1188.
22.
KimTB, OhYM, ChangYS, ChoYS, JangAS, ChoSH, et al; COREA and KOLD Study Group. The reality of an intermediate type between asthma and COPD in practice. Respir Care, 2012; 57(8):1248-1253.
23.
SilvaGE, SherrillDL, GuerraS, BarbeeRA. Asthma as a risk factor for COPD in a longitudinal study. Chest, 2004; 126(1):59-65.
24.
VonkJM, JongepierH, PanhuysenCI, SchoutenJP, BleeckerER, PostmaDS. Risk factors associated with the presence of irreversible airflow limitation and reduced transfer coefficient in patients with asthma after 26 years of follow up. Thorax, 2003; 58(4):322-327.
